Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Abstract Background The efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients harboring neurotrophin receptor kinase (NTRK) family mutations remains obscure. Methods The Zehir cohort from cBioPortal was used to analyze the mutations (MT) frequency of NTRK fam...

Full description

Bibliographic Details
Main Authors: Xiaoling Shang, Wengang Zhang, Wenfei Han, Handai Xia, Ni Liu, Xiuwen Wang, Yanguo Liu
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Pulmonary Medicine
Subjects:
Non-small cell lung cancer
NTRK family mutation
Immune checkpoint inhibitors
Tumor mutational burden
PD-L1 expression
Overall survival
Online Access:https://doi.org/10.1186/s12890-023-02707-x

Internet

https://doi.org/10.1186/s12890-023-02707-x

Similar Items